[Demonstration of platelet-specific alloantibodies in HLA-sensitized hematologic oncologic patients].
Alloimmunization to the platelet-specific antigen systems HPA-1, -3 and -5 was studied in 59 multitransfused patients (31 females, 16 males, 12 children) with haematologic-oncologic disorders. All patients tested had broad-reacting or multispecific HLA antibodies. Of these, 10 (17%) were found to have additional platelet-specific alloantibodies. With respect to HLA sensitization, 9 out of 10 platelet-specific alloantibodies were found in sera which showed HLA antibodies reacting with more than 95% of unselected panel cells. Determination of antibody specificity revealed 6 patients with anti-HPA-1b, one patient with anti-HPA-3a, and 2 patients with anti-HPA-1b combined with anti-HPA-3a. One patient had anti-HPA-5b; in retrospect, only the HPA-5b antibody was demonstrable before the beginning of transfusion therapy and before HLA sensitization.
Schnaidt
M
M
Abteilung für Transfusionsmedizin mit Blutbank, Universität Tübingen, Deutschland.
Wernet
D
D
Mayer
G
G
Northoff
H
H
D000328:Adult; D000918:Antibody Specificity; D016824:Antigens, Human Platelet / Q000276:immunology*; D001803:Blood Transfusion; D002648:Child; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D008297:Male
D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007518:Isoantibodies
Nachweis thrombozytenspezifischer Alloantikörper bei HLA-sensibilisierten hämatologisch-onkologischen Patienten.